Liver fibrosis represents a health problem with significant morbidity and mortality that affects
100 million people worldwide. It is a final pathway to several chronic liver diseases and is …

Pirfenidone is an orally active small molecule that has recently been evaluated in large
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …

Increased collagen expression in tumors is associated with increased risk of metastasis, and
triple-negative breast cancer (TNBC) has the highest propensity to develop distant …

The morbidity and mortality of hepatic fibrosis caused by various etiologies are high
worldwide, and the trend is increasing annually. At present, there is no effective method to …

Liver damage leads to an inflammatory response and to the activation and proliferation of
mesenchymal cell populations within the liver which remodel the extracellular matrix as part …

Treatment of chronic kidney disease (CKD) can slow its progression to end-stage renal
disease (ESRD). However, the therapies remain limited. Blood pressure control using …

Renal fibrosis is the hallmark of virtually all progressive kidney diseases and strongly
correlates with the deterioration of kidney function. The renin-angiotensin-aldosterone …

Fibrosis is a pathological reparative process that can occur in most organs and is
responsible for nearly half of deaths in the developed world. Despite considerable research …

Pirfenidone (PFD) is a non-peptide synthetic molecule issued as a broad-spectrum anti-
fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression …

Abstract Background and Objectives: Pirfenidone is an orally available antifibrotic agent that
has shown benefit in animal models of pulmonary and renal fibrosis and in clinical trials of …